Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol-Enhanced CBT for Generalized Anxiety Disorder
NCT07123467Phase 3Recruiting
- Sponsor
- Wayne State University
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in generalized anxiety disorder (GAD) (4 arms), sponsored by Wayne State University. Primary endpoint: Change in dorsomedial prefrontal cortex activation when reappraising negative images at 5 weeks. Started Nov 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07123467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123467.